Evotec was named in a Goldman Sachs filing showing 10.93% of its voting rights, mostly through financial instruments. The notice says nothing about Evotec's business, so it does not change the outlook.
The filing tracks voting rights, not Evotec's sales, drug research, or finances. Most of the reported position comes through financial instruments, and the notice gives no business consequence for Evotec. That leaves no clear business change to point either way.
Goldman Sachs reported 10.93% of Evotec's voting rights, mostly through financial instruments. The notice describes a holdings filing, not a change to Goldman Sachs's business, so its outlook is unchanged.
Follow Evotec SE (EVO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for EVO